about
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.EGFR soluble isoforms and their transcripts are expressed in meningiomas.RIZ1 negatively regulates ubiquitin-conjugating enzyme E2C/UbcH10 via targeting c-Myc in meningioma.Pediatric meningioma: current approaches and future direction.Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective seriesCucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.The Role of Mifepristone in Meningiomas Management: A Systematic Review of the LiteratureBrain meningioma invading and destructing the skull bone: replacement of the missing bone in vivo.Malignant intrasellar meningioma presenting as an invasive pituitary macroadenoma: A rare case report and literature review.Regression of Intracranial Meningioma during Treatment with α1-Adrenoceptor Blocker.Medical treatment of recurrent meningiomas.Atypical and anaplastic meningiomas treated with bevacizumab.Chemotherapy: What is its role in meningioma?Medical management of meningiomas.Resilience and Coping Strategies Influencing the Quality of Life in Patients With Brain Tumor.Genomic landscape of high-grade meningiomas.Checkpoint inhibition in meningiomas.Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.Expression of astrocyte elevated gene-1 (AEG-1) in human meningiomas and its roles in cell proliferation and survival.Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin AnaloguesRecurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin.Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutationsPIK3CA mutations in meningioma.PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.Systemic therapy for recurrent meningioma.2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies.Preoperative and postoperative prediction of long-term meningioma outcomesEmerging Medical Treatments for Meningioma in the Molecular Era
P2860
Q30361848-5B56CED3-8ED4-447D-A8B0-4E771FDEF3A2Q30393860-D28AD997-84EB-4261-BC62-9DC0FB582C25Q30458310-F23950BC-AE4B-488A-88E1-185A3780F379Q31062214-D462FC38-B716-409D-BDC5-5116A958B0BFQ33733305-63CA8311-EA3D-4B46-8D44-EABAE16174CFQ33785024-2C3B3EB4-1EDC-494D-B82D-E5F08B6B33C2Q34246609-98605F03-1B1B-4365-825B-1FFC34898EE1Q34492943-5F30584E-6E28-454C-BD03-B0F3FDEDF6AAQ34716061-B46A38A6-DCFB-4E2C-9C98-6DB03E57142DQ35106253-60B2432F-B25C-4075-B72C-29A7ACAA138DQ35683023-E4C4053B-EF30-48C7-840F-3F23CBF27E21Q36177827-877BDAFD-341E-4781-88C5-61613C168439Q36523894-88CBB850-3EB6-4DBD-AA42-1C6B25FBA710Q36892210-749CC878-D0A9-4978-B530-6B50945FB575Q37939997-AB0AE18A-10FA-496D-8028-7FC6332C38A8Q38006444-CED5975A-CC00-42F5-A823-93C89BB8EF39Q38053441-5073237A-E1ED-41D6-B9C9-14EA5B899B61Q38233448-50152FB3-D128-49FA-9856-42C50561A6DCQ38665523-CF0F0692-4A24-442B-859B-AB039E3E2DCCQ38676440-08395261-2F46-4B9E-936A-85D9800C85EBQ38838646-7BDF8158-7DDD-416A-84B3-538A7E00267DQ38938019-4D343872-CA28-47ED-93BC-2BD790F82B1EQ38960386-23F41D7B-1901-4A04-8FF5-FB478E46D520Q38979594-51C2988F-831E-43C9-A54B-D4DD1EE631D0Q39615481-06E1593D-8F03-478A-8F2C-CD91D573C074Q40867510-4A780D32-4F96-4B68-9892-9691A2A252C4Q41236574-979F8015-E8C7-4B5A-8251-AFFE7B29895FQ41488554-8F28F145-ACFE-4AE8-8E2D-10752783A077Q42548316-7636C0DB-0A06-4AA1-BAF8-0AC8573BC8CCQ42908544-415AB345-8A22-463B-ABC1-CBBC4FFEF0B2Q46058355-0038C486-CF71-4E21-8BF2-7DF19C04F142Q48787594-34B8A555-07FC-4876-9885-505C7AF14B68Q51159183-FCA863DB-6828-453D-84F5-9AAFDD804C3FQ57588609-943DA121-3F12-4580-8B28-31C80029F521Q58798211-345FD333-6AB9-4708-B3F8-8B671C52DB8A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Medical therapies for meningiomas.
@en
Medical therapies for meningiomas.
@nl
type
label
Medical therapies for meningiomas.
@en
Medical therapies for meningiomas.
@nl
prefLabel
Medical therapies for meningiomas.
@en
Medical therapies for meningiomas.
@nl
P2093
P2860
P1476
Medical therapies for meningiomas.
@en
P2093
Andrew D Norden
Eudocia Quant
Jan Drappatz
Patrick Y Wen
Rameen Beroukhim
P2860
P2888
P304
P356
10.1007/S11060-010-0349-8
P577
2010-09-04T00:00:00Z